MMIT recently held a syndicated simulated P&T session focused on the approvals of ruxolitinib cream (Opzelura), lebrikizumab, and tralokinumab for atopic dermatitis.
Be the first to know about new arrivals and promotions
Reducing Risk: 5 Steps for a Fearless Launch
